These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35181194)

  • 1. Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-293.
    Dong C; Chen SL; Sung WW
    Eur Urol; 2022 May; 81(5):e123. PubMed ID: 35181194
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-93.
    Welen K; Rosendal E; Freyhult E; Fors Connolly AM; Överby AK; Josefsson A
    Eur Urol; 2022 May; 81(5):e124-e125. PubMed ID: 35168845
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-93: Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients.
    Wambier CG; Nau GJ
    Eur Urol; 2022 Jun; 81(6):e141-e142. PubMed ID: 35304000
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients.
    Welén K; Rosendal E; Freyhult E; Oh WK; Gisslén M; Ahlm C; Connolly AF; Överby AK; Josefsson A
    Eur Urol; 2022 Jun; 81(6):e143-e144. PubMed ID: 35248411
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Liam Bourke, Stephen Gilbert, Richard Hooper, et al. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol 2014;65:865-72; Re: Daniel A. Galvão, Nigel Spry, James Denham, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol 2014;65:856-64; Re: Nancy L. Keating, Pang-Hsiang Liu, A. James O'Malley, Stephen J. Freedland, Matthew R. Smith. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014;65:816-24; Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014;65:704-9.
    Goonewardene SS; Persad R; Young A; Makar A
    Eur Urol; 2014 Sep; 66(3):e51-2. PubMed ID: 24813269
    [No Abstract]   [Full Text] [Related]  

  • 6. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data.
    Welén K; Rosendal E; Gisslén M; Lenman A; Freyhult E; Fonseca-Rodríguez O; Bremell D; Stranne J; Balkhed ÅÖ; Niward K; Repo J; Robinsson D; Henningsson AJ; Styrke J; Angelin M; Lindquist E; Allard A; Becker M; Rudolfsson S; Buckland R; Carlsson CT; Bjartell A; Nilsson AC; Ahlm C; Connolly AF; Överby AK; Josefsson A
    Eur Urol; 2022 Mar; 81(3):285-293. PubMed ID: 34980495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9 and re: John Anderson. Androgen-deprivation therapy--It's all a matter of timing. Eur Urol 2008;53:869-71.
    Kirollos MM
    Eur Urol; 2009 Feb; 55(2):e40-2; author reply e45-6. PubMed ID: 18760526
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Adam G. Sowalsky, Stephen R. Plymate, Michael C. Haffner, Johann S. de Bono, and Adam Sharp's Letter to the Editor re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol 2021;79:879-86: AR-V7 is Rare in Hormone-sensitive Prostate Cancer.
    Li H; Zhang Y; Xu H
    Eur Urol; 2022 Nov; 82(5):e137-e138. PubMed ID: 36088181
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Frans Debruyne, Arkadij A. Gres, Dmitrii L. Arustamov. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist Cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170-80.
    Drewa T; Chlosta P
    Eur Urol; 2009 Feb; 55(2):e36-7; author reply e38-9. PubMed ID: 18703271
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Claude C. Schulman, Jacques Irani, Juan Morote, et al. Androgen-deprivation therapy in prostate cancer: a European expert panel review. Eur Urol suppl 2010;9:675-91.
    Langley RE; Price P; Abel PD
    Eur Urol; 2011 Apr; 59(4):e24-5; author reply e26. PubMed ID: 21255905
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Vincenzo Pagliarulo, Sergio Bracarda, Mario A. Eisenberger, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012;61:11–25.
    Cornel EB
    Eur Urol; 2012 Jun; 61(6):e59; author reply e60. PubMed ID: 22386192
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Rhonda L. Bitting, Patrick Healy, Daniel J. George, et al. Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. Eur Urol Oncol 2021;4:948-54.
    Guler OC; Isci O; Onal C
    Eur Urol Oncol; 2022 Aug; 5(4):477-478. PubMed ID: 35307322
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31.
    Ghadjar P; Wiegel T
    Eur Urol; 2019 Mar; 75(3):e61-e62. PubMed ID: 30670365
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Russell Szmulewitz, Supriya Mohile, Edwin Posadas, et al. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 2009;56:97-104.
    Friedman AE
    Eur Urol; 2009 Nov; 56(5):e36; author reply e37. PubMed ID: 19683856
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.
    Tombal B
    Eur Urol; 2014 Apr; 65(4):e56. PubMed ID: 24380648
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9.
    Ragavan N; Singh PB; Martin FL; Baird AD
    Eur Urol; 2009 Feb; 55(2):e43-4. PubMed ID: 18771846
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Bernard Tombal's letter to the editor re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.
    Sciarra A
    Eur Urol; 2014 Apr; 65(4):e57. PubMed ID: 24388442
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium. Eur Urol. 2022;82:106-14.
    Lao Y; Wang Y; Dong Z
    Eur Urol; 2022 Sep; 82(3):e80-e81. PubMed ID: 35688661
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.015.
    van Soest RJ; de Wit R; van Weerden WM
    Eur Urol; 2014 Oct; 66(4):e71-2. PubMed ID: 25012524
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Ofer Yossepowitch, Anders Bjartell, James A. Eastham, et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 2009;55:87-99.
    Kynaston H; Parker CC; Sydes MR;
    Eur Urol; 2009 Jun; 55(6):e107. PubMed ID: 19303202
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.